MX358099B - Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos. - Google Patents

Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.

Info

Publication number
MX358099B
MX358099B MX2013013360A MX2013013360A MX358099B MX 358099 B MX358099 B MX 358099B MX 2013013360 A MX2013013360 A MX 2013013360A MX 2013013360 A MX2013013360 A MX 2013013360A MX 358099 B MX358099 B MX 358099B
Authority
MX
Mexico
Prior art keywords
methods
immunodeficiency virus
human immunodeficiency
antibodies
neutralize
Prior art date
Application number
MX2013013360A
Other languages
English (en)
Other versions
MX2013013360A (es
Inventor
Scheid Johannes
Nussenzweig Michel
J Bjorkman Pamela
Diskin Ron
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of MX2013013360A publication Critical patent/MX2013013360A/es
Publication of MX358099B publication Critical patent/MX358099B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos ampliamente neutralizantes dirigidos a epítopos del Virus de Inmunodeficiencia Humana, o VIH. La invención también provee composiciones que contienen anticuerpos de VIH usadas para la profilaxis y métodos para el diagnóstico y el tratamiento de la infección por VIH.
MX2013013360A 2011-05-17 2012-05-17 Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos. MX358099B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486960P 2011-05-17 2011-05-17
PCT/US2012/038400 WO2012158948A1 (en) 2011-05-17 2012-05-17 Human immunodeficiency virus neutralizing antibodies adn methods of use thereof

Publications (2)

Publication Number Publication Date
MX2013013360A MX2013013360A (es) 2014-09-22
MX358099B true MX358099B (es) 2018-08-06

Family

ID=47177348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013360A MX358099B (es) 2011-05-17 2012-05-17 Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.

Country Status (19)

Country Link
US (6) US9783594B2 (es)
EP (2) EP2710033B1 (es)
JP (6) JP6323718B2 (es)
CN (4) CN103797029B (es)
AU (6) AU2012255266B2 (es)
CA (1) CA2836468C (es)
CY (1) CY1124043T1 (es)
DK (1) DK2710033T3 (es)
EA (2) EA032929B1 (es)
ES (1) ES2895523T3 (es)
HR (1) HRP20210375T1 (es)
HU (1) HUE053545T2 (es)
IL (4) IL295205B2 (es)
LT (1) LT2710033T (es)
MX (1) MX358099B (es)
PL (1) PL2710033T3 (es)
PT (1) PT2710033T (es)
SI (1) SI2710033T1 (es)
WO (1) WO2012158948A1 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012255266B2 (en) 2011-05-17 2017-05-25 California Institute Of Technology Human immunodeficiency virus neutralizing antibodies and methods of use thereof
US9493549B2 (en) 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
US9890207B2 (en) 2011-07-25 2018-02-13 California Institute Of Technology Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
US9879068B2 (en) 2012-06-21 2018-01-30 California Institute Of Technology Antibodies targeting HIV escape mutants
US10308707B2 (en) * 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US10421803B2 (en) 2014-01-31 2019-09-24 The Rockefeller University Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
US10676521B2 (en) * 2014-07-21 2020-06-09 The Rockefeller University Combination of broadly neutralizing HIV antibodies and viral inducers
AU2015326911C1 (en) * 2014-09-30 2025-12-18 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (DPRs) antibody
EP3209699A1 (en) * 2014-10-22 2017-08-30 Crescendo Biologics Limited Vh scaffold
CN104697830B (zh) * 2015-02-10 2018-06-15 深圳市新产业生物医学工程股份有限公司 用于hiv检测的酸性处理剂、样本预处理方法、试剂盒及检测方法
SMT202000255T1 (it) 2015-03-20 2020-07-08 The United States Of America As Represented By The Secretary Department Of Health And Human Services Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo
MX2018005048A (es) 2015-10-25 2018-09-06 Sanofi Sa Proteinas de union triespecificas y/o trivalantes para la prevencion o el tratamiento de la infeccion por vih.
AU2016349392B2 (en) 2015-11-03 2023-07-13 The Trustees Of Columbia University In The City Of New York Neutralizing antibodies to HIV-1 gp41 and their use
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3423091A4 (en) 2016-03-03 2019-10-30 Duke University COMPOSITIONS AND METHODS OF INDUCING HIV-1 ANTIBODIES
SI3443006T1 (sl) 2016-04-13 2024-01-31 Sanofi Trispecifični in/ali trivalentni vezni proteini
BR112018070998A2 (pt) 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
CN105968200B (zh) * 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
EP3519428A4 (en) * 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
WO2018075564A1 (en) 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
AU2017387041B2 (en) 2016-12-27 2024-12-12 California Institute Of Technology Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof
WO2018169926A1 (en) * 2017-03-14 2018-09-20 Oregon State University Peptide inhibitors targeting the neisseria gonorrhoeae pivotal anaerobic respiration factor ania
EP3600405B1 (en) 2017-03-24 2025-08-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
US20200172601A1 (en) 2017-06-22 2020-06-04 University Of Maryland, Baltimore Broadly neutralizing antibodies against hiv
CN120058938A (zh) 2017-10-10 2025-05-30 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
WO2019165122A1 (en) 2018-02-21 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2019173802A1 (en) * 2018-03-09 2019-09-12 Atreca, Inc. Anti-hiv antibodies
CN110305219B (zh) * 2018-03-27 2021-05-04 清华大学 一种包含嵌合抗原受体（car）修饰的t细胞在制备细胞药物中的用途
CA3097872A1 (en) 2018-04-27 2019-10-31 Biogen Ma Inc. Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody
EP3802572A4 (en) * 2018-05-25 2022-03-23 Temple University - Of The Commonwealth System of Higher Education REMOVAL OF BACTERIAL BIOFILM USING ANTI-AMYLOID MONOCLONAL ANTIBODIES
MX2020012519A (es) 2018-06-11 2021-02-16 Dow Global Technologies Llc Maquinas cortadoras y metodos para formar rollos de peliculas recubiertas con estas.
CN116731283A (zh) 2018-06-11 2023-09-12 陶氏环球技术有限责任公司 制造涂布膜的方法和可以用于制造涂布膜的无溶剂聚氨基甲酸酯前体
CR20200653A (es) 2018-07-03 2021-02-11 Gilead Sciences Inc Anticuerpos que se dirigen al gp120 de vih y métodos de uso
JP2022500042A (ja) * 2018-09-14 2022-01-04 ザ ロックフェラー ユニバーシティー 抗ｈｉｖ抗体１０−１０７４バリアント
WO2020072169A1 (en) 2018-10-01 2020-04-09 Duke University Hiv-1 envelope stabilizing mutations
MX2021004147A (es) 2018-10-09 2021-09-08 Sanofi Sa Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
US12534516B2 (en) * 2018-10-22 2026-01-27 International Aids Vaccine Initiative Anti-HIV antibodies
LT3938047T (lt) 2019-03-22 2022-10-10 Gilead Sciences, Inc. Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202231277A (zh) * 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP3831848A1 (en) * 2019-12-02 2021-06-09 Universität zu Köln Broadly neutralizing antibodies against hiv
JP7711068B2 (ja) 2019-12-24 2025-07-22 カルナバイオサイエンス株式会社 ジアシルグリセロールキナーゼ調節化合物
TW202146463A (zh) * 2020-03-05 2021-12-16 法商賽諾菲公司 蛋白酶加工的分子
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
JP7712352B2 (ja) 2020-08-07 2025-07-23 ギリアード サイエンシーズ， インコーポレイテッド ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用
MX2023002194A (es) 2020-08-25 2023-03-03 Gilead Sciences Inc Moleculas multiespecificas de union a antigenos dirigidas al vih y metodos de uso.
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4660325A3 (en) 2020-11-11 2026-02-25 Gilead Sciences, Inc. Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN115518151A (zh) * 2021-06-24 2022-12-27 前沿生物药业(南京)股份有限公司 一种人类免疫缺陷病毒中和抗体制剂及其用途
US20240352445A1 (en) * 2021-08-13 2024-10-24 Abwiz Bio, Inc. Humanization, affinity maturation, and optimization methods for proteins and antibodies
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
KR20240128090A (ko) 2021-12-31 2024-08-23 베이징 솔로바이오 진테크놀로지 컴퍼니 리미티드 Hiv 감염 세포를 표적으로 하는 키메라 항원 수용체 t 세포
WO2023158505A1 (en) * 2022-02-16 2023-08-24 Prothione Llc Compositions and methods for the treatment of human immunodeficiency virus
EP4499227A1 (en) 2022-03-26 2025-02-05 The United States of America, as represented by The Secretary, Department of Health and Human Services Bispecific antibodies to hiv-1 env and their use
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
JP2025523043A (ja) 2022-07-12 2025-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
CN121358478A (zh) 2023-04-19 2026-01-16 吉利德科学公司 衣壳抑制剂的给药方案
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
WO2024249592A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
AU2023460182A1 (en) 2023-07-28 2026-02-05 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
AU2023462614A1 (en) 2023-08-23 2026-03-19 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
CN117275589A (zh) * 2023-08-28 2023-12-22 大理大学 Hiv抗体亲和性预测方法、系统、设备及介质
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080879A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202530227A (zh) 2023-10-11 2025-08-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184416A1 (en) 2024-02-27 2025-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single-domain antibodies and bispecific antibodies against hiv-1 and their use
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
IL89567A0 (en) 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
US5445960A (en) * 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
WO1993003151A1 (en) 1991-08-10 1993-02-18 Medical Research Council Treatment of cell populations
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2213148T3 (es) 1993-03-11 2004-08-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anticuerpo monoclonal dirigido contra el vih.
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
ATE207760T1 (de) * 1993-05-07 2001-11-15 Akzo Nobel Nv Hiv immunogene komplexe
WO1996016673A1 (en) 1994-12-02 1996-06-06 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
ATE440861T1 (de) * 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
WO2002068649A2 (en) 2001-01-31 2002-09-06 Curagen Corporation Proteins and nucleic acids encoding same
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
AU2002355477B2 (en) * 2001-08-03 2008-09-25 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
WO2003044036A1 (en) 2001-11-19 2003-05-30 Applied Molecular Evolution, Inc. Tumor specific monoclonal antibodies
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
US20030232387A1 (en) 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
US7824681B2 (en) * 2005-08-16 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies that specifically bind IGF-II
EP2016173A4 (en) * 2006-05-15 2010-06-09 Immunomedics Inc METHOD AND COMPOSITIONS FOR TREATING HUMAN IMMUNODEFECT VIRUS INFECTIONS WITH CONJUGATED ANTIBODIES OR ANTIBODY FRAGMENTS
JP4895727B2 (ja) * 2006-08-28 2012-03-14 シスメックス株式会社 抗ｈｉｖ抗体検出試薬、試薬キット、試薬の製造方法、及び抗ｈｉｖ抗体の検出方法
MX2010001918A (es) 2007-08-21 2010-03-11 Amgen Inc Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino.
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2098536A1 (en) * 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
EP2281845B1 (en) 2008-04-25 2020-09-02 Kyowa Kirin Co., Ltd. Stable polyvalent antibody
MX2010013565A (es) * 2008-06-30 2011-01-14 Novo Nordisk As Anticuerpos de interleucina-20 anti-humanos.
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
ES2553440T3 (es) 2009-08-13 2015-12-09 Crucell Holland B.V. Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
EP2480572B1 (en) 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
WO2012154312A1 (en) * 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
AU2012255266B2 (en) * 2011-05-17 2017-05-25 California Institute Of Technology Human immunodeficiency virus neutralizing antibodies and methods of use thereof
US9493549B2 (en) * 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
US9890207B2 (en) * 2011-07-25 2018-02-13 California Institute Of Technology Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
CA3236192A1 (en) * 2012-10-18 2014-04-24 The Rockefeller University Broadly-neutralizing anti-hiv antibodies
US10676521B2 (en) * 2014-07-21 2020-06-09 The Rockefeller University Combination of broadly neutralizing HIV antibodies and viral inducers

Also Published As

Publication number Publication date
JP6323718B2 (ja) 2018-05-16
CA2836468C (en) 2021-05-04
HRP20210375T1 (hr) 2021-07-09
EA201391713A1 (ru) 2014-07-30
CY1124043T1 (el) 2022-05-27
AU2020201993A1 (en) 2020-04-09
AU2012255266A1 (en) 2013-12-19
JP2020202827A (ja) 2020-12-24
EP2710033B1 (en) 2021-01-20
IL229469B (en) 2020-08-31
US12071470B2 (en) 2024-08-27
AU2012255266B2 (en) 2017-05-25
IL295205B2 (en) 2024-11-01
EP2710033A4 (en) 2015-04-22
JP2014516527A (ja) 2014-07-17
CN103797029A (zh) 2014-05-14
CN106432484B (zh) 2020-10-30
JP7622953B2 (ja) 2025-01-28
US20240254206A1 (en) 2024-08-01
AU2020201993B2 (en) 2022-03-31
PL2710033T3 (pl) 2021-10-25
CN112225798B (zh) 2023-07-18
US20210230254A1 (en) 2021-07-29
US9783594B2 (en) 2017-10-10
EA201990685A1 (ru) 2019-12-30
IL295205A (en) 2022-10-01
AU2019200972A1 (en) 2019-02-28
US11634478B2 (en) 2023-04-25
US12428472B2 (en) 2025-09-30
DK2710033T3 (da) 2021-03-08
IL276182B (en) 2022-09-01
CA2836468A1 (en) 2012-11-22
IL229469A0 (en) 2014-01-30
JP7076721B2 (ja) 2022-05-30
MX2013013360A (es) 2014-09-22
US20260062465A1 (en) 2026-03-05
WO2012158948A1 (en) 2012-11-22
PT2710033T (pt) 2021-03-11
JP2024001150A (ja) 2024-01-09
AU2025204249A1 (en) 2025-06-26
JP7368812B2 (ja) 2023-10-25
LT2710033T (lt) 2021-06-10
SI2710033T1 (sl) 2021-05-31
AU2022204340B2 (en) 2025-03-06
CN106432484A (zh) 2017-02-22
US20180079800A1 (en) 2018-03-22
JP7801721B2 (ja) 2026-01-19
AU2019200972B2 (en) 2020-04-16
IL276182A (en) 2020-09-30
EP2710033A1 (en) 2014-03-26
IL313030A (en) 2024-07-01
JP6720242B2 (ja) 2020-07-08
AU2022204340A1 (en) 2022-07-14
JP2022115945A (ja) 2022-08-09
HUE053545T2 (hu) 2021-07-28
ES2895523T3 (es) 2022-02-21
US20140328862A1 (en) 2014-11-06
US20230365661A1 (en) 2023-11-16
AU2017204563B2 (en) 2018-11-22
BR112013029550A2 (pt) 2022-04-19
EP3865507A1 (en) 2021-08-18
US10889633B2 (en) 2021-01-12
IL295205B1 (en) 2024-07-01
AU2017204563A1 (en) 2017-07-27
CN103797029B (zh) 2016-08-17
CN112225798A (zh) 2021-01-15
CN116948019A (zh) 2023-10-27
JP2018161126A (ja) 2018-10-18
JP2025061692A (ja) 2025-04-11
EA032929B1 (ru) 2019-08-30

Similar Documents

Publication Publication Date Title
MX358099B (es) Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
MX2016003216A (es) Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
MX369307B (es) Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana.
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
NI201700019A (es) Anticuerpos anti tigit
MX386403B (es) Anticuerpos humanos para hemaglutinina de influenza.
MX2017001279A (es) Usos y composiciones de la flagelina.
MX346206B (es) Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.
MX391043B (es) Formulaciones de anticuerpo y metodos.
MX370191B (es) Composiciones y su uso en el tratamiento de la inmunodeficiencia.
MX2014013678A (es) Agentes para neutralizacion de influenza.
UY35993A (es) Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina
IN2014MN01907A (es)
MX349235B (es) Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs).
PE20160596A1 (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana
MX2016000037A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
WO2014040025A3 (en) Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
BR112017003252A2 (pt) terapia com anticorpos contra hiv como substituto de tratamento
UY34128A (es) Métodos, composiciones y kits para determinar el virus de la inmunodeficiencia humana (vih)?.
MX386783B (es) Compuestos peptidomiméticos que neutralizan el virus influenza.
ECSP17016755A (es) Anticuerpos anti tigit
AR095869A1 (es) Anticuerpos humanos que se unen a la proteína g del rsv
CU20140006A7 (es) Moléculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenético 1 y grupo filogenético 2 y virus de la influenza b

Legal Events

Date Code Title Description
FG Grant or registration